Navigation Links
Helix BioPharma Closes Private Placement
Date:9/8/2009

AURORA, Ontario, Sept. 8 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP"; OTCQX: "HXBPF") today announced that it has closed its previously announced private placement of 6,625,000 units at $2.05 per unit.

Each unit consists of one common share and one common share purchase warrant, with each common share purchase warrant entitling the holder to purchase, subject to adjustment, one common share of the Company at a price of $2.87 for up to three years after the closing date of the private placement. Net proceeds after expenses are expected to be approximately $11.7 million and will be used for working capital, primarily to support the Company's expanding clinical trial initiatives.

The securities offered will not be and have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is listed on the TSX and FSE under the symbol "HBP" and the OTCQX International Market under the symbol "HXBPF".

    For further information contact:

    Investor & Media Relations
    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel:  (212) 845-4226
    Email: robert.flamm@russopartnersllc.com

    Ian Stone
    Russo Partners LLC
    Tel:  (619) 814-3510
    Fax: (619) 955-5318
    Email: ian.stone@russopartnersllc.com

    www.russopartnersllc.com

This News Release contains certain forward-looking statements and information regarding Helix BioPharma Corp. ("Helix" or the "Company"), its proposed use of proceeds of the private placement, its estimated net proceeds of the placement, and its clinical trial and development initiatives, which statements and information can be identified by the use of forward looking terminology such as "will", "estimated", "expanding", and "developing". Helix's actual results could differ materially from these forward-looking statements and information as a result of numerous risk factors, including without limitation, the risk that that the net proceeds of the placement may be different than estimated and may be used for purposes other than those currently intended; research & development risks, which may result in material changes to, or the termination of, the Company's clinical trial and development initiatives; and Helix's continuing need for additional future capital to carry on its business, which may not be available. The latter two risks and uncertainties, and others affecting the Company, are more fully described in the Company's latest MD&A, Form 20-F, and other reports filed with the Canadian Securities Regulatory Authorities and the U.S. S.E.C. from time to time at www.sedar.com, and www.sec.gov/edgar.shtml, respectively. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations change, except as required by law.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma Announces $13.5 Million Private Placement
2. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
3. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
4. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
7. Helix BioPharma to Present at the BioFinance 2009 Conference
8. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
9. Helix BioPharma Announces Q2 2009 Financial Results
10. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
11. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... Vortex ... posters at the American Association for Cancer Research (AACR) Annual Meeting 2017 ... Vortex’s technology to rapidly collect highly enriched populations of CTCs, undamaged by labels ...
(Date:3/29/2017)... ... March 29, 2017 , ... Zansors announced today ... as issued by the U.S. Patent & Trademark Office (USPTO). The patent covers ... and health monitoring. This invention will be critical to the future of wearable ...
(Date:3/29/2017)... "Surging application of gesture control features in ... expected to drive the growth of gesture recognition and ... is expected to be worth USD 18.98 billion by ... and 2022. The touchless sensing market is expected to ... a CAGR of 17.44% between 2017 and 2022. Gesture ...
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, risk and ... 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The Summit will take ... Boston, MA. , The Omni Parker House Hotel, which is located at 60 School ...
Breaking Biology Technology:
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
Breaking Biology News(10 mins):